• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
  • Contact Us
A SARS-CoV-2 NSP7 homolog of a Treg epitope suppresses CD4+ and CD8+ T cell memory responses

A SARS-CoV-2 NSP7 homolog of a Treg epitope suppresses CD4+ and CD8+ T cell memory responses

by Elena Iemma | Nov 27, 2023

Immunogenicity risk assessment of synthetic peptide drugs and their impurities

Immunogenicity risk assessment of synthetic peptide drugs and their impurities

by Elena Iemma | Jul 27, 2023

Immunogenicity risk assessment of synthetic peptide drugs and their impurities – ScienceDirect
Identification of a potent regulatory T cell epitope infactor V that modulates CD4+ and CD8+ memory T cell responses

Identification of a potent regulatory T cell epitope infactor V that modulates CD4+ and CD8+ memory T cell responses

by Annie De Groot | Jan 13, 2021

FV621 De Groot et al 2021
Immune camouflage: Relevance to vaccines and human immunology

Immune camouflage: Relevance to vaccines and human immunology

by Annie De Groot | Jan 13, 2020

De Groot et al. – 2014 – Immune camouflage Relevance to vaccines and human immunology

Recent Posts

  • Thinking Out Loud in March
  • Optimize Your Immunogenicity Strategy with Trusted Expert Advice 
  • EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements
  • Thinking Out Loud in February
  • Thinking Out Loud: January 2025

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline